FDA Aligns with Calidi’s CLD-401 Strategy, Clearing Path for 2027 Human Trials
Event summary
- FDA provided positive pre-IND feedback on Calidi’s CLD-401 development strategy, aligning on IND-enabling preclinical plans and clinical study design.
- CLD-401, an oncolytic virus with IL-15 superagonist delivery, targets non-small cell lung cancer and head and neck cancer.
- Calidi aims to submit an IND application for CLD-401 by year-end 2026, with first-in-human trials expected in early 2027.
- The company’s RedTail platform enables systemic delivery of genetic medicines to metastatic tumor sites.
The big picture
Calidi’s FDA alignment positions it to advance CLD-401, a novel oncolytic virus, into human trials. The RedTail platform’s ability to deliver genetic medicines systemically could disrupt traditional cancer treatments, particularly for metastatic diseases with high unmet medical needs. The company’s progress reflects broader industry trends toward targeted, precision therapies in oncology.
What we're watching
- Regulatory Momentum
- Whether the FDA’s alignment accelerates Calidi’s path to market for CLD-401, reducing potential delays in Phase 1 trials.
- Clinical Validation
- How early Phase 1 data for CLD-401 will validate the RedTail platform’s efficacy in targeting metastatic cancers.
- Strategic Partnerships
- The pace at which Calidi secures partnerships to expand the RedTail platform’s clinical applications beyond oncology.
Related topics